GSK Reports Results of Benlysta (belimumab, IV) in P-III BLISS-LN Study for Patients with Active Lupus Nephritis

 GSK Reports Results of Benlysta (belimumab, IV) in P-III BLISS-LN Study for Patients with Active Lupus Nephritis

Shots:

  • The P-III BLISS-LN study involves assessing of IV belimumab 10 mg/kg + standard therapy vs PBO in 448 patients with active lupus nephritis for 104 wks.
  • P-III BLISS-LN study results: met 1EPs and all major 2EP; Primary Efficacy Renal Response (PERR) (43% vs 32%); showed consistent safety results; ORR was defined as complete  
  • Benlysta is a mAb and a BLyS-specific inhibitor designed for binding to soluble BLyS further inhibiting the survival of B cells. The company plans for regulatory submissions based on P-III results in H1’2020

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post